% | $
Quotes you view appear here for quick access.

Novavax, Inc. Message Board

  • montleycarista montleycarista Jun 23, 2013 12:12 PM Flag


    Over a quarter of a century has elapsed while Novavax has diluted the stock on a daily basis, they still have not figured out how to make vaccines. Don't take my word for it, google it....

    Buying shares of Novavax is akin to turning over your money to the greedy, lying management team.

    Before you bagholders start yapping again, answer this question, "How many APPROVED vaccines does Nvax have on the market after almost 27 years of daily dilutions".

    The answer is ZERO.... and will remain ZERO

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • So if you are so down on this stock why don't you leave? You are not down on it, in fact you love it and want others shares. Don't you? You just want a better price that's all. I bought more last week so you don't get them. I will buy more this week as well. Up on my purchase as well.

      You still have not provided any proof that NVAX even existed 25 or 26 or27 years ago. I am not sure how many years because you keep changing your mind. I have asked you several times but you don't asnswer because you can't. Your credability is O. Have a great weekend.

      Sentiment: Strong Buy

      • 1 Reply to ltdobanion
      • You spend too much attacking others and not enough time knowing about your bad investments.

        Business Summary
        Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company’s technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines. Its vaccine candidates target seasonal influenza, pandemic (H5N1) influenza, and respiratory syncytial virus (RSV). The company, through its joint venture, CPL Biologics Private Limited, engages in developing seasonal and pandemic influenza, and rabies vaccine candidates. The company has a licensing agreement with LG Life Sciences, Ltd. to use the company’s VLP technology to develop and sell the influenza vaccines in South Korea and other countries; and a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Rockville, Maryland.

        Sentiment: Strong Sell

    • So then you shouldn't buy any shares.....? More for me =)

      Sentiment: Strong Buy

7.18+0.31(+4.51%)Aug 26 4:00 PMEDT